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Abstract 
This dissertation was written as part of the MSc in Management at the International Hellenic 
University.  
The present study will aim at examining Food Testing & Diagnostics, focused on Mycotoxins. An 
analysis on the nature of Mycotoxins, the methods used to detect and quantify them and 
development of this niche market, will be provided. Market shares, geographical divisions, major 
players and prospects of the sector will be demonstrated, while general features and an overview 
of the sector’s margins will be analyzed. 
The goal of this dissertation is to evaluate the current position of the companies of the sector, in 
correlation to the market’s evolution during the past 10 years and projections for the next 5, at 
least. Our findings demonstrate a rapidly growing sector due to the increasing awareness and the 
climate change which provokes mycotoxin infestation. Along with this trend, consecutive rounds 
of consolidation in the sector have established economies of scale, facilitating major players in 
achieving greater margins, despite the intense competition among them.  
Finally, I want to thank my supervisor, Dr. Archontakis, for the great collaboration and help during 
the past months.  
 
Konstantinos-Platon Chitzos 
31/01/2018 
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Ch. 1: Introduction 
There is no term which can exactly describe the market of food analysis and safety. Behind the 
curtains, an unknown, to the broader public, world analyzes food and animal feed before it is 
processed and forwarded to the wholesale and retail points. 
Especially in the past 50 years, since trade has become global and food has followed along the 
lines of international commerce, needs of Quality Control/Assurance have arisen throughout the 
globe. The public is aware of the most common dangers that can be faced when eating carelessly, 
such as salmonella, listeria and e. coli. 
As Food Technology advances and food is processed in massive volumes, more and more 
parameters are considered and tested in internal or external (professional) laboratories. The 
aforementioned parameters are being tested by using specific methods developed by chemical 
companies producing specific, high-added value reagents. This market began forming in the late 
1970s and today is growing rapidly, more than 6% annually. Its name differs, according to who is 
investigating but the most common terms are: Food Testing and Food Diagnostics. 
Parameters tested are usually split into two broad categories: Microbiology (Salmonella, Listeria, 
E. coli, Campylobacter, etc.) and Physico-chemical analysis (Allergens, Mycotoxins, Food 
Adulteration, Antibiotics). According to Markets & Markets, the size of the market is more than 
12 bil. USD (Markets & Markets Annual Report on Food Testing Market by Food Tested, 2017), 
which is not an impressive number, but the margins and growth are flabbergasting.  
In the following chapters we will present an overview of the diagnostics sector focusing on 
Mycotoxins, while at the same time we shall try to assess the dominant companies and the trends 
that are formed in the market within the past 10 years. Due to the high specialization of the 
sector itself, we shall proceed to a broader and detailed investigation of the parameters forming 
and determining the market, as well as the technical characteristics of the products at stake. 
The goal of this dissertation is to give an overview of the Mycotoxins diagnostics market and the 
major components of it, while a detailed analysis of the phenomena will visually facilitate the 
reader in comprehending its structure. Tools such as Porter’s Five Forces, a regular SWOT 
analysis, as well as a PESTLE one, will be used in order to provide the landscape of the market. 
An extensive financial analysis on the 3 major players will be conducted, since the Big 3 constitute 
more than 90% of the market’s sales worldwide (ProGnosis Biotech own data, 2017). Interesting 
ratios such as capital structure, profitability and activity ones, will demonstrate the strategic 
steps taken by almost all companies, regardless the size. 
Concluding, it is necessary to distinguish the evolving tendencies from the dynamic but 
decelerating changes in the sector. Before understanding the finance behind the scene, it is 
imperative to comprehend the science. Technical terms, methods and correlation to specific 
mycotoxins will be exhibited in order to provide the reader with a complete and broad idea on 
the sector. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ch. 2: Mycotoxins & Testing 
2.1 Food Testing & Diagnostics  
In our current investigation we shall focus on the Physico-chemical category and specifically on 
Mycotoxins, which is a group of toxins excreted by specific fungi, such as Aspergillus Flavus, 
Penicilium and Fusarium, under very common circumstances. These toxins are potent 
carcinogenic substances, as officially stated by the World Health Organization, and have come 
into the spotlight only during the past 10 years. A market of more than 1.5 bil. USD has evolved 
during the past years, including all methods of testing Immunoassays and Chromatography 
methods (Business Wire Annual Report on Mycotoxin Testing Market, 2017). They officially 
constitute one of the most common causes of occurrence of liver cancer in humans, while their 
impact on animals is multi-dimensional and can be observed only when the damage is 
irreversible. 
Mycotoxins are a group of toxins produced by mainly three different fungi, but not exclusively. A 
sub-group, Aflatoxins was discovered in 1960 but it took years until their impact was evaluated 
and their potency quantified. Virtually until the ‘90s, Aflatoxin testing was rare and carried out 
almost exclusively at entry-points (customs). Awareness increased in the early 2000s, specifically 
in 2003, when more than 100 countries agreed on legislating at least Aflatoxins. While Aflatoxins 
were in the spotlight, introduced as extremely potent and declared as officially carcinogenic, 
more Mycotoxins were observed and defined.  
Gradually, awareness grew, and the big push came from the common legislative effort of the EU, 
Regulation 1881/2006 (EC Regulation 1881, 2006), which regulated the most common 
Mycotoxins in nature: Aflatoxins, DON, Zearalenone, Ochratoxin A, Fumonisins. Since 2006, 
additions and amends have been made to keep up the pace with the relevant scientific 
developments. Sampling obligations, recommended and official methods were introduced and 
guidelines to all member-states, constituted a solid framework on which food safety went to 
another level.  
Among other difficulties, detecting and quantifying Mycotoxins is a very delicate process which 
takes place either on the field, after harvest, or in the food processor’s premises. Three different 
methods are used worldwide, in different combinations, adjusting to different legislations and 
mentalities. Level of awareness is the major factor contributing in the formation of each country’s 
system of testing. It is impossible to consider Mycotoxin prevention without state aid and a 
holistic approach from the authorities and the private sector, at least on a country level. 
These three methods overlap but at the same time clearly demonstrate specific advantages and 
disadvantages according to how they are used and how seriously the user takes Mycotoxins. One 
could virtually say that the specific market is unexplored and that it will grow rapidly in the next 
years. As gluten (most common allergen tested) has become a trend in testing (Markets & 
Markets Annual Report on Food Allergen Testing Market by Source, 2017) so will Mycotoxins as 
awareness grows and sustainable (financially and time-wise) methods have been developed. 
2.2 Methods of Mycotoxin testing 
Immunoassays, simply speaking, are assays based on the principle of an antibody binding with a 
specific antigen which exists in the food tested. Although we currently omit several crucial details 
and important aspects, it is imperative to keep it simple throughout our investigation.  
Three different types of immunoassays have been developed during the past 40 years and they 
have witnessed the fall of their competitors. Immunochromatographic Tests (also called Lateral-
Flow Tests or Rapid Tests) constitute the most recent evolution in food testing, simplifying testing 
on-site, allowing the user to accept or reject a truck upon reception. 
On-site testing, as a pre-emptive action is always crucial but testing further down the line, before 
processing, inside the laboratory is also necessary. Lateral-flow tests currently are the “first line 
of defense”, while ELISA (Enzyme-Linked Immunosorbent Assay) is the par excellence method in 
an industry’s laboratory. This method is recommended for multiple but not consecutive samples 
to be tested. ELISA plates are produced in two formats, of 48 and 96 wells, while Rapid Tests are 
unique strips which test samples on-by-one in less than 10 minutes each (Rapid Microbiology 
article, 2017). 
ELISA kits are boxes containing plates of 48 or 96 wells and the chemical reagents needed to 
conduct an experiment. Basic laboratory tools are needed in order to proceed. Results are “read” 
by using a spectrophotometer, which gives you Values of Light Absorbance, which in turn are 
extrapolated into quantities of Mycotoxins by the relevant software. On the other hand, Lateral-
flow tests are strips which are dipped into the sample and reaction takes place on the strip. 
Results are read by a relevant reader or scanner and extrapolated into quantities of Mycotoxins 
by the relevant software. 
Finally, Chromatography (HPLC or LC/MS-MS), a very expensive initial investment followed by 
equally expensive consumables are usually found in external laboratories, rarely in the industry 
laboratories, and are ideal for the analysis of very small numbers of samples annually (less than 
2.000). Regarding Mycotoxins, it is the official method of testing for all the EU institutions 
(customs, reference laboratories, etc.) and a certificate is required to conclude an export 
(European Commission JRC Validated Methods, 2013). Main disadvantage is its ability to test one 
sample at a time, although for multiple Mycotoxins, and the time needed to prepare the sample. 
ELISA and Lateral-flow tests are less accurate methods which are less time-consuming and cost-
effective, while they require no specialization and any kind of educational background of the 
user. Due to Mycotoxin crisis of 2008 and 2013, sampling has risen, and industries have decided 
to intensify testing in-house. Some of them have even established their own professional 
laboratories in order to control testing in a larger scale. 
As long as awareness increases, and industries test more, ELISA and Rapid Tests’ markets will be 
growing, while HPLC is gradually replaced by a more evolved chromatography solution called 
LC/MS-MS. Virtually, chromatography will remain stagnant due to a trend of testing being 
“transferred” in the industry and away from the professional laboratories. 
2.3 Use of Diagnostic products 
Industries as well as laboratories analyze samples for different reasons, but with a common goal: 
providing the necessary “green light” for the next stage of manufacturing. In some countries, 
universities incorporate professional laboratories and provide services to the industries. Finally, 
customs also test imported products in order to assure their quality. 
Starting from the main recipient which is the average food industry, raw materials, such as milk, 
corn, wheat and spices are tested in the field or at collection centers, before being forwarded to 
the processing facilities. Raw materials must be tested in a fast fashion, virtually screening, which 
can be done only by Lateral-flow test: fast and with low requirements in prior training. Further 
analysis is done upon reception at the plant, especially when materials are imported; in turn, this 
means storage and transportation involved, which can result into fungal growth and toxin 
excretion.  
In dried fruit, nuts and flour industries, samples are also taken after the first process step (shell 
crushing, wheat milling, etc.) in order to reduce probability of fungal growth during the interval 
between reception and processing. This interval is very common, for example, in animal feed 
industries, where silos contain tens of tones of grains, in storage, until they are forwarded in feed 
production. 
 Hence, risks arise in different occasions in an industrial production line, which translates into 
multiple sampling taking place and analysis needed to be done as soon as possible. This results 
in ELISA being selected over Lateral-flow so as to reduce cost per sample and test all samples 
simultaneously (Rapid Microbiology article, 2017). When an industry does not follow this chain 
of sampling and testing, their only alternative is to dispatch a very small number of samples 
annually to external laboratories.  
In the end of the production line, a final sampling per lot production is the most common 
rationale found worldwide. In this case, legislative restrictions and need for reliable results drive 
food industries to dispatch samples to external laboratories, or purchase Chromatography 
equipment which can be disproportionately expensive as an initial investment and the 
consumables required.  
Imminence and costs are the drivers of the food industries, fast solutions coupled with lower 
costs. In the laboratories’ sector, accuracy and quality of results are the principal goals, since 
testing is done is retrospective and the relatively small number of samples drives 
Chromatography testing. Prices charged are very high per sample (more than 80 euros per 
sample, regardless the country and disposable income) since Chromatography demands 
expensive consumables and depending on the samples, highly-skilled and committed users. 
In-house chromatography would cost an industry one-third of the aforementioned price per 
sample, but the initial investment of 60,000 euros in a traditionally neglected department such 
as Quality Control, would render the investment improbable. In contrast, ELISA and Lateral-flow 
can be used by the average laboratory user, regardless his degree, without ever exceeding the 
cost of 8 euros per sample and dropping as the number of samples rises. Moreover, the initial 
investment does not exceed 5,000 euros, in the case of top-tier instruments. 
As testing shifts from the laboratory sector (services) to the food industry itself and Aflatoxin 
crisis are present, and detected too, ELISA methods are evolving; the gap between 
chromatography and ELISA is closing. An equivalent trend is the improvement of Lateral-flow 
tests since they have become more acceptable to the public, despite their inaccuracy. 
A sound projection to the future would be the revival and consolidation of ELISA as an “accurate” 
method (ProGnosis Biotech own data, 2017), fully incorporated in industrial testing, while it will 
surely attain a respectable market share from the “traditional” Chromatography player, HPLC. In 
the meanwhile, the evolved Chromatography method, LC/MS-MS, although it requires an even 
greater initial investment (three to four times the HPLC initial cost), it is much easier to use and 
requires less consumables, will gradually replace HPLC in laboratories. Lateral-flow tests will have 
to be improved further in order to face the challenge of an expanding ELISA market share, and 
all-in-all become a worldwide testing tool for the food industries. 
In addition to the previously mentioned absolution of the HPLC method, universities and customs 
in the EU have already switched to LC/MS-MS, since high accuracy is a prerequisite and the 
annual number of samples is rather low. Universities in some countries substitute public 
laboratories by offering equivalent services enhanced by the esteem deriving from a public 
institution. Developing economies, where private laboratories are not so common because of the 
constraints on private initiative, usually have public laboratories and universities developing a 
net of testing and controlling private and public food industries. 
Despite all we have said above, if it were not for the customs testing imported products, no food 
industry or public institution would have performed any kind of control. As in most cases, 
Mycotoxins, and particularly their sub-group, Aflatoxins, where “discovered”, one could say 
“drew attention”, in 1960 when a bulk of contaminated peanut meal (animal feed) caused the 
death of thousands of chickens and turkey (Toxins Reviews, 2008). By tracing back to the 
imported shipment, the UK authorities established a system of testing upon arrival. They were 
followed by other European countries, although it was the US that pushed forward in developing 
methods and establishing common rules on testing. 
Customs tend to draw samples per shipment, although this could be characterized as insufficient 
and not at all representative, it is impossible to multiply the sampling done at their premises due 
to the needs that will emerge regarding personnel. Moreover, customs are not at the spear-point 
of evolution therefore they are not aware of the developments taking place in terms of the 
methods and their accuracy.  
Although insufficient, customs’ checking eventually obligated exporting companies to test and as 
testing grew, more problems came into the light. This in turn, resulted into tighter internal 
control and finally into routine in-house testing. As food trade becomes more and more global 
and along with it, awareness over the dangers it bears, Mycotoxins will be sought further, and 
legislation will become more refined and sophisticated. 
  
 
 
 
 
 
 
 
Ch.3: Financial Analysis & Competition Landscape 
As discussed above, Mycotoxin diagnostics could be considered as a niche market since the total 
turnover is barely over 1.5 billion USD. Chromatography (HPLC and LC/MS-MS) and Immuno-
assays (ELISA and Lateral-flow) constitute the only methods used worldwide in detecting and 
quantifying mycotoxins.  
Regarding the manufacturers, one could say that the market is quite concentrated, mainly in the 
hands of two big players: Neogen Corp. and R-Biopharm AG. These 2 companies offer a broad 
range of products in which Mycotoxins play a primary role. Their capability of offering 
consumables for all 3 technologies, HPLC, ELISA and Lateral-flow, renders them as the 
undisputable leaders of the general food testing sector. It is important to clarify that our focus is 
on the manufacturers, not the service providers, such as SGS, Intertek, Eurofins, etc. These are 
huge laboratories offering services of which food constitutes only a small part, and do not 
produce chemical reagents. 
During the past couple of years, some of these laboratories have entered the secondary 
production by acquiring smaller manufacturers. As we are talking about manufacturing, it is 
important to note that Neogen and R-Biopharm produce also Clinical Diagnostics’ kits and strips, 
such as pregnancy tests, which we will not consider. 
Our interest is production of chemical reagents used for food analysis, specifically for Mycotoxins. 
This extremely specialized and narrow spectrum, leaves us with a rather small competitive 
landscape, where Neogen presents a turnover of more than 300 million USD. R-Biopharm is 
second with half the turnover and then we have a drop down to 30 million USD. Although it is 
quite small as a market, comparing to other biotechnology markets at least, the margins are 
probably among the highest worldwide.  
Gross profit margins rarely drop below 40%, while smaller companies tend to achieve up to 60% 
(ProGnosis Biotech own data, 2017), since they do not have the ability of discounting parts of one 
product range and compensate by entering a specific customer with 2 or more different ranges. 
What is really unique in the sector is the fact that not even the biggest company, Neogen Corp., 
has any debt, long or short-term. Due to the great margins and exponential growth, greater or 
smaller companies followed conservative policies in terms of investments, implemented by 
private equity instead of debt. Moreover, due to the fact that all of the companies are not listed 
and family-owned, they follow a policy of not distributing dividends, instead re-investing profits. 
Even Neogen, a public company, listed in NASDAQ, has released less than 20% of its shares to 
investors which are not related to the main shareholder. Return on Equity (ROE) rates are very 
high throughout the sector, ranging from 16% to more than 20%, which would be a wild scenario 
for an average heavy industry. Even lighter industries, focusing on consumer goods wouldn’t 
dream of such a rate. 
ROA starts from a lower level but escalates to the same, exceedingly high levels. It is apparent 
that companies established in the biotechnology sector invest heavily on Assets, mostly 
equipment and edifices. Facilities and equipment receive heavy investments, while inventories 
are rare in biotechnology. Biotech products tend to have short shelf-lives (rather improbable to 
find anything above 12 months), and consumptions, especially in the Mycotoxins field fluctuate 
considerably. 
Stock controlling is one of the most important issues, since due to automated production systems 
but crucial human design, labor cost per item drops sharply when producing specific numbers of 
items. It is true that the same workhours will be consumed for the production of 1 ELISA kit or 50 
ELISA kits (ProGnosis Biotech own data, 2017). The same thing applies to Lateral-flow tests. 
Finally, due to continues investments and the relative depreciations occurring, and due to the 
fact that R&D is indirectly subsidized in almost all advanced and advancing countries worldwide 
through tax deductibility, taxation does not have a substantial impact on EBT. Extra taxation is 
avoided by rare dividend distributions. 
There are only four multinational companies which have subsidiaries in different continents; the 
rest of the manufacturers are too small to bear the costs of operating subsidiaries. Neogen Corp., 
R-Biopharm, RomerLabs (Erber Group) and Envirologix Inc. are multinational companies, while 
Tecnalab and VICAM are parts of the multi-national groups of Eurofins and PerkinElmer 
respectively, but do not have any subsidiaries. 
Charm Sciences, Helica Biosystems and ProGnosis Biotech are the sole “family-owned” 
enterprises. Of course, a big number of Chinese companies produce Lateral-flow tests for 
Mycotoxins, but they are not significant in the worldwide market and the statistics following 
these companies are questionable. Therefore, we will focus on these 9 groups/companies. 
Collecting information was quite difficult, since only Neogen is a public company and the rest of 
them, even R-Biopharm, are not very open in terms of publishing information. For example, the 
total sum of the acquisition of Tecnalab Srl, by Eurofins, has not been disclosed yet, almost 2 
years later. It was not mentioned even in the Eurofins annual report. Below, we will focus in 
analyzing the 3 major multinationals, Neogen, R-Biopharm and Romer Labs and geographically 
presenting market shares. 
3.1 Neogen Corporation 
The leader of the market in food testing, established in 1982, is also one of the two major players 
in Mycotoxins’ testing. Based in Lansing, Michigan, US, Neogen is a market leader in the US and 
has strategically acquired more than 30 companies during the past 20 years. Through acquisitions 
it has consolidated a broad range of products on Food Safety and Animal Safety, rising from 
24.228 mil. USD to 321.275 mil. USD in 2016, demonstrating a staggering increase of at least 10% 
annually for 17 consecutive years. 
Operating income rose from 5.186 mil. USD to 56.386 mil. USD mainly due to the complete 
absence of any long-term debt. Throughout the years, growth was based on private equity and 
strategic acquisitions funded also by private equity.  
Net income rose from 2.374 mil. USD to 36.564 mil. USD, while the contribution of Food Safety 
products has declined gradually from 50% of the turnover in 2000 to 40% in 2016. Natural toxins, 
allergens and drug residues (mainly antibiotics), demonstrated sales of 63.259 mil. USD, steadily 
rising with at least 5% per annum.  
During the past 5 years, profit margins, gross and net, have slightly declined to competition 
intensification, but mostly due to the increasingly aggressive policy implemented by smaller, 
independent players. Neogen prefers to lose existing customers instead of reducing its margins; 
that is why distributor prices are aligned with the competitors’, major and minor, although its 
positioning is “premium quality for a premium price”. Most Neogen distributors enjoy excellent 
margins, sometimes even more than 40%. 
Table 1. Neogen ratios during past 5 years 
 
Continuous and steady growth is coupled by increasing equity, while liabilities grow slowly and 
are mostly short term. Although Neogen is a US company, with direct access to a banking system 
which rewards credibility, it presents no debt, either short- or long-term. Return Rates, ROA, ROE 
and ROS are quite steady but in contrast to its major competitor, R-Biopharm, an apparent gap 
is observed. This is mostly due to the fact that R-Biopharm utilizes 3 technologies in almost every 
parameter tested, and has dominated the ELISA market of allergens, especially Gluten. 
In terms of technologies, Neogen produces both Lateral-flow and ELISA kits, but does not produce 
any consumables for Chromatography, which automatically bars the company from entering an 
extremely lucrative market. Although, Immunoassays (ELISA & Lateral-flow) comprise more than 
99% of the turnover in food industries, they contribute less than 20% in professional laboratories. 
2012 2013 2014 2015 2016
Turnover $184,046,000 $207,528,000 $247,405,000 $283,074,000 $321,275,000
Gross Profit $92,425,000 $109,494,000 $122,598,000 $139,685,000 $153,064,000
EBITDA $35,835,000 $40,706,000 $43,391,000 $53,118,000 $56,386,000
EBT $33,839,000 $41,141,000 $43,031,000 $52,076,000 $55,513,000
Net Income $22,513,000 $27,190,000 $28,158,000 $33,526,000 $36,564,000
Total Assets $251,600,000 $290,558,000 $345,301,000 $392,181,000 $451,715,000
Liabilities $32,546,000 $32,271,000 $39,001,000 $41,218,000 $47,554,000
Equity $218,839,000 $258,221,000 $306,361,000 $350,974,000 $404,198,000
Gross Profit margin 50.22% 52.76% 49.55% 49.35% 47.64%
Net Profit margin 12.23% 13.10% 11.38% 11.84% 11.38%
Return on Equity 10.29% 10.53% 9.19% 9.55% 9.05%
Return on Assets 8.95% 9.36% 8.15% 8.55% 8.09%
Return on Sales 19.47% 19.61% 17.54% 18.76% 17.55%
Total Average Assets $235,530,000 $271,079,000 $317,929,500 $368,741,000 $421,948,000
Total Assets Turnover ratio 78.14% 76.56% 77.82% 76.77% 76.14%
Liabilities to Equity ratio 14.87% 12.50% 12.73% 11.74% 11.77%
Exports constitute more than 40% of the total turnover, on average, having risen from less than 
20% in 2000. Currently it employs more than 1.300 people worldwide. 
3.2 R-Biopharm AG 
The second major player in Food Diagnostics and a close competitor of Neogen in Mycotoxins’ 
diagnostics, R-Biopharm was founded in 1988 as a subsidiary of Rohm AG. In 1991 it was taken 
over by the current owner, Ralph Dreyer, and gradually developed into a company exporting to 
96 countries and operating 23 subsidiaries in key markets. It is not a public company although 
there was a plan of entering the stock market in 2008. 
Currently it employs more than 800 people all around the globe, while exports constitute more 
than 80% of its turnover. The group demonstrated sales surpassing 140 mil. EUR, rising annually 
more than 10%. It is a company focused on producing ELISA kits for Mycotoxins, Allergens and 
Microbiology. Within the range of products some qualitative and quantitative Lateral-flow sticks 
can be found, but they do not constitute core products. 
An interesting feature in R-Biopharm’s financial statement is the complete absence of any long-
term debt. All acquisitions have been funded by private equity and expansion has been achieved 
methodically throughout the past 20 years. In contrast to its major opponent, Neogen, the 
German company developed a strategy of creating subsidiaries in core markets, optimizing sales 
& distribution. It does not incorporate productive companies, since R&D and production are 
concentrated in the Headquarters. 
Net income rose to more than 18 mil. EUR in 2016, rising steadily more than 10% annually. In 
order to demonstrate the company’s evolution, it is important to note that the group’s turnover 
in 2000 was less than 10 mil. EUR. In contrast to its major competitor, Neogen, gross and profit 
margins demonstrate an interesting annual increase of at least 3-4%, due to the dominant 
position in the allergens market as well as the continuous development of Lateral-flow tests for 
mycotoxins, in order to achieve penetration in previously untapped markets. 
Table 2. R-Biopharm ratios during the past 5 years 
 While equity and assets are growing fast, liabilities grow disproportionately slow in comparison 
to the rest of the rates, indicating investment fueled by shareholders’ equity. Edifices, high-tech 
equipment and hiring skilled personnel constitute more than 95% of any investment 
implemented by R-Biopharm. 
3.3 Romer Labs GmbH 
Tom and Mary Romer founded Romer Labs in 1982 and developed a company focused on 
Mycotoxins which gradually expanded to Europe. The acquisition by Erber Group in 1999, 
internationalized Romer Labs, since Erber group evolved in a group focused on 2 strategic 
directions: incorporating different companies of relative areas (such as Biomin which produces 
mycotoxin binders and relevant solutions) and creating subsidiaries in key markets in order to 
optimize sales & distribution. 
Romer Labs is an export-oriented company, almost 95% of its turnover comes from exports and 
it operates subsidiaries in 7 countries worldwide, focusing in Brasil, China and South-East Asia. It 
is not a public company, and has a single owner, Erber Group. Romer currently employs more 
than 400 employees in Austria and its subsidiaries. 
2012 2013 2014 2015 2016
Turnover 60,708,000 € 64,570,000 € 74,518,000 € 75,950,000 € 81,343,000 €
Gross Profit 35,754,000 € 38,158,000 € 43,247,000 € 44,962,000 € 49,507,000 €
EBITDA 14,322,000 € 15,892,000 € 20,110,000 € 18,246,000 € 22,136,000 €
EBT 13,374,000 € 15,071,000 € 18,890,000 € 16,863,000 € 20,408,000 €
Net Income 9,726,000 € 11,228,000 € 14,821,000 € 12,166,000 € 14,789,000 €
Total Assets 50,907,000 € 64,134,000 € 82,871,000 € 86,627,000 € 103,829,000 €
Liabilities 5,316,000 € 10,250,000 € 17,102,000 € 12,741,000 € 17,178,000 €
Equity 45,693,000 € 54,067,000 € 66,032,000 € 74,273,000 € 87,163,000 €
Gross Profit margin 58.90% 59.10% 58.04% 59.20% 60.86%
Net Profit margin 16.02% 17.39% 19.89% 16.02% 18.18%
Return on Equity 21.29% 20.77% 22.45% 16.38% 16.97%
Return on Assets 19.11% 17.51% 17.88% 14.04% 14.24%
Return on Sales 23.59% 24.61% 26.99% 24.02% 27.21%
Total Assets Turnover ratio 119.25% 100.68% 89.92% 87.67% 78.34%
Since Romer is a part of a highly profitable corporation, Erber Group which presented sales of 
more than 300 mil. Euros in 2016, and due to the conservative nature of the major shareholders, 
Romer Labs GmbH has also no debt, either short-term or long-term. 
As it is not a public company, listed in any stock exchange, Romer Labs tends to keep data 
regarding its financial activities obscure. Moreover, although Romer Labs is present in more than 
6 countries around the globe, these subsidiaries are in fact companies directly linked only to Erber 
Group, rendering it extremely difficult to fully assess the true turnover and margins of Romer 
Labs as a diagnostics-oriented enterprise. 
3.4 Geographical division & Market shares 
Before proceeding to further analysis of the relevant financial data, it would be very useful to 
distinguish market shares, trends and geographical penetration for all contenders.  
Starting with the geography in scope, we must consider that the US and Europe are on the spear-
tip of biotech developments. Wherever there are manufacturers, there is the market itself. 
Awareness in Europe regarding Mycotoxins grew before anywhere else in the world but was 
surpassed by the magnitude of the US grain production, an especially corn. As discussed 
previously, corn is the most susceptible product to Mycotoxins and the US is by far the greatest 
producer worldwide (All About Feed, 2014). Along with a very strict and well-planned 
enforcement of Food Safety Acts, the US became the home of various biotech companies 
producing ELISA kits and Lateral-flow tests.  
Throughout the ‘90s and ‘00s, while Europe, especially the countries lying on the Mediterranean 
coast, was still working with Chromatography and voluntarily avoided to address the Mycotoxin 
issue, the US, Canada and Mexico moved forward as the legislative forces shifted responsibility 
to the industries. Compelling them to test “every truck upon reception” created the need for 
something faster than ELISA, in the early ‘00s, NAFTA countries (huge corn & wheat producers) 
had already moved to the Lateral-flow phase. In Europe, due to several crises an ELISA market 
developed and within the past 5 years, Lateral-flow came into the game, but ELISA is still 
considered to be more reliable than the average lateral-flow test. 
As multinational companies, like Nestle, Danone, Lactalis and Unilever expand further in Asia, 
mycotoxin testing tends to become a priority; especially in countries such as China and India, 
where testing has become a priority during the past 10 years, growth is exponential. Forecasts 
are that within the following 10 years China, but India even more, will represent more than 90% 
of the market’s growth. Apparently, by establishing subsidiaries in both countries, the major 
players want to consolidate shares in the largest and unspoiled markets worldwide. The Brazilian 
and US market, although extremely big, are regarded as saturated due to the intense competition 
with medium enterprises, such as Envirologix and Charm, and the natural saturation charactering 
a fully evolved market. 
In contrast to other physico-chemical and microbiological parameters, it is important to 
understand that Mycotoxins are not present all around the globe, surely not with the same 
frequency, and seasonality is also a factor which must be taken into account. For example, 
Oceania records extremely low contamination levels, equivalent to the British Isles and 
Scandinavia. One the other hand, areas such as sub-Saharan African and Central America, 
although facing consistently mycotoxin issues, have not evolved into substantial markets. 
Unfortunately, in countries such as Nigeria, Angola, South Africa, Costa Rica, Honduras, food 
companies are not mainly export-driven and therefore choose to neglect mycotoxin testing.  
Mature and substantial markets are the NAFTA countries, Mercosur member and EU countries 
affected by the Mediterranean climate. Turkey as well as Iran should be considered as 
developing, the “next best things” in the Middle East, while China and India are rapidly growing. 
ASEAN countries can also be characterized as developing but haven’t really evolved due to the 
consolidation of the 3 major players in the area. 
 
 
 
 
Ch. 4: PESTLE Analysis 
4.1 Political-Legal Framework 
Although food safety is not mainly a political issue, the impact of severe poisoning, 
circumstantially resulting in death, on the government’s publicity can be considerable. 
Microbiology, describing Salmonella, Listeria and Campylobacter are the most common factors 
alarming a Health Ministry, but in 2013, Aflatoxin contamination in corn, produced in Serbia, 
Croatia and Romania, caused considerable tension between the Health Ministries of Serbia and 
Germany, which was the destination of the raw material (Wikipedia, 2013 European Aflatoxin 
Contamination). 
Equivalent problems were caused in Greece and Cyprus. In Greece, Greenpeace published a 
questionnaire it had sent to the biggest Greek dairies; a series of questions regarding internal 
Aflatoxin testing, which along with the answers, or reluctance to answer, were exposed to the 
public, caused a political reaction from the Ministry of Health. Public institutions which had 
supposedly monitored the industry were caught off guard and attempted to compensate by 
drawing multiple samples on a regular basis during the months of the crisis.  
In Cyprus, an outrage against the government compelled the Ministry of Health to enhance the 
responsibilities of the local Veterinary services and oblige mills to test for Aflatoxins in animal 
feed. 
A few years earlier in the US, a severe Mycotoxin crisis resulted in an open discussion on what 
was considered to be a minor issue. This discussion resulted in the Food Sanitary Act of 2011 
which articulated the necessary procedures and strategic actions taken against Mycotoxins. 
Last but not least, in 2008, China was shocked by the death of 12 infants and the hospitalization 
of more than 54.000 (Wikipedia, 2008 Chinese Milk Scandal). This was due to an extensive 
melamine contamination, which resulted in officials being executed and a frenzy of testing had 
just begun. Aflatoxin M1, the hydroxylated metabolite of Aflatoxin B1, had become equally 
important to melamine. Even Hu Jintao, China’s president, referred to the problem called 
Aflatoxin.  
If the crisis and alarms were the edifice on which modern food safety control was built, the 
foundations of global awareness were laid in 2003 when more than 100 countries agreed to 
legislate Aflatoxins. Some of them went further; food-exporting countries which had never 
before even tested for DON, Zearalenone or Fumonisins, implemented a full legislative 
framework complemented by Maximum Residue Limits (MRL). In 2006, the EU put in force the 
1881/2006 Regulation which was followed by the World Health Organization’s declaration of 
Aflatoxins and Ochratoxin A as “Carcinogenic” and the rest of the regulated Mycotoxins as 
“Possibly Carcinogenic”. 
This series of political and legal events led to a political, and consequently legislative, framework 
which obliges industries, institutions and consumers to control quality and raises concerns on 
food safety. Mycotoxins and allergens are the “next best thing” in the food diagnostics’ sector. 
4.2 Economic framework 
Mycotoxins can have a devastating impact on the agricultural balance worldwide. As previously 
discussed, Mycotoxins are among the most potent chemical compounds which can be detected 
in food. Moreover, due to the fact that they appear frequently on both wheat and corn, which 
are the most common agricultural products used for human consumption and animal feed, they 
literally affect every human or animal meal on the planet.  
Additionally, mycotoxins cannot be eradicated or degraded by any kind of treatment (for example 
intense heat treatment) and it is impossible to trace them in non-liquid elements, due to the fact 
that homogenization is far more complete in fluids. This is the reason milk and wine are tested; 
detecting mycotoxins in solid elements (corn kernels, flour, etc.) is merely a matter of probability. 
As an example, we could state that 4 kernels of corn among the billions in a silo, can be enough 
so as the ruminant excretes milk contaminated above regulated levels. Mycotoxins, although 
produced by fungi are not necessarily present when the fungus is present. Mold does not 
necessarily mean Mycotoxins, but also vice versa. The mold might be eradicated, but the toxins 
will remain, if they have already been excreted.   
Therefore, the only solution would be destroying the infected bulk. This would result in huge 
economic losses, which have been calculated approximately to more than 25% of the global trade 
value of agricultural products (Mycokey, Mycotoxins & Effects). It is impossible for any institution, 
public or private, to shoulder this cost. The only realistic and feasible action is a constant dilution 
of contaminated batches with uncontaminated batches. 
Of course, this is also faces natural constraints. What is apparent, is that testing has to be done 
in all stages after harvest until the product reaches the final consumer. Sampling must be 
considered as the most important factor and milk has to be tested, because it’s easy to miss a 
contaminated corn truck, but it’s impossible to miss a contaminated milk tank. 
The number of crisis and scandals since 2008 in different areas of the planet have cost billions of 
dollars, regardless whether the economy of a country is large or smaller. This is why most 
countries out of the EU have a much higher Maximum Residue Limit (MRL) for Aflatoxin M1 in 
milk, set at 500 ppt (parts per trillion); by raising the limit more milk or corn is considered 
acceptable and not to be discarded. In the EU, the 50 ppt (parts per trillion) limit for Aflatoxin M1 
in milk, has caused a great deal of problems, especially in the Mediterranean area where 
Aflatoxins thrive. 
The most prominent case of legislation re-adjustments in order to avoid economic disaster is, 
still, taking place in Serbia. It is important to note down that the country is among the top 15 corn 
producers worldwide and a self-sufficient country in terms of animal feed. Unfortunately, corn is 
optimally grown under conditions which are equally optimal for Aflatoxin excretion. As 
aforementioned, corn is the number one susceptible matrix to Aflatoxins. 
In early 2011, Serbia adopted a limit of 500 ppt for Aflatoxin M1 in milk. As the 2011 and the 2012 
corn harvests were quite good in terms of Aflatoxins, the Ministry of Agriculture decided to lower 
the limit to 50 ppt in, so as to achieve a 100% alignment with EU regulations. As winter progressed 
and storing and transporting infrastructure were exposed, Aflatoxins rose rapidly and resulted in 
a mass contamination in milk, starting early January 2013 (Mljekarstvo Journal, 2016). 
More than 80% of milk was contaminated above the 50 ppt limit and should be incinerated. 
Things were even worse in corn-based animal feed. Dairy industries and milk producers officially 
and publicly demanded that the government raised the limit back to 500 ppt, or else the 
economic impact would be unbearable. The government responded rapidly accepting the dairies’ 
demand and raised the limit 10-fold. Losses were limited to 100 million USD (huge amount if we 
take into account that the annual state expenditures are approximately 16 billion USD).  
Serbia lowered the limit in 2015, to 250 ppt, only to raise it again to 500 ppt in 2016. Once more, 
although in a much lesser extent, the Serbian government abided to the industry’s demand. 
Virtually, a demand for survival. Since 01/01/2017 the limit was lowered back to 250 ppt but 
indications do not permit a further reduction to the EU limit (50 ppt). 
 
4.3 Social framework 
When you take into account everything stated in the above lines, it is possible to comprehend 
the impact Mycotoxins contamination would have on society. Public health is always revered, 
Increased political intervention
Publicity - High media coveage
Chinese melamine outbreak 
Economic impact on farmers
Losses of approximately 25% of world food and feed output
Increasing rate of cancer
Awareness accompanied by conferences and publications
Evolution of testing methods
Further sophistication of Quality Control systems
Broader range of analytes tested
Impact on livestock and ruminants in general
Reduction of tillage and use of pesticides
Sophistication of legislation starting with the Food Sanitary Act in the US
Blobal convention in 2003 where common steps in mycotoxins legislation was 
decided
when it’s in the spotlight. The other side of the coin, in contrast to the previous discussion about 
the economic impact, is the impact on society’s health.  
Mycotoxins are “silent killers”, as mycotoxicosis is an asymptomatic process. Cumulatively, the 
liver, which metabolizes these specific chemical compounds, is toxified and cancer becomes 
imminent. Moreover, estrogenic anomalies, intestinal pains and diarrhea subdue the subject.  
Governments must consider the impact on public health and the economic losses. Consumers 
are nowadays aware of Aflatoxins, not to the true extent, but publications on Aflatoxins have 
quadrupled during the past 5 years and articles are published. This is the status in the EU and 
North America. Asian countries, whose climate is ideal for Aflatoxin excretion, such as India, 
Pakistan and ASEAN countries, have not appreciated the magnitude of the problem (Journal of 
Pure and Applied Microbiology, 2013).  
Especially in India and Pakistan, milk samples tested demonstrate contaminations which by any 
standard should be considered unsafe. As in the case of antibiotics’ residues, it takes a few years 
until the scientific knowledge is diffused and legislators decide to act. 
As long as the media talks about it and universities educate the future chemists and food 
technologists, Aflatoxins will be a globally recognizable concern. As societies advance 
economically, standards are raised, quality in food is prioritized, while poisonings and deaths due 
to food contamination cause public outrage.  
Unfortunately, the rest of the Mycotoxins are currently in the shade. For most laboratory 
technicians, Mycotoxins are just another set of parameters to be tested. No discriminations are 
made and all of them are, more or less, the same in the mind of the industry. 
Due to the fact the rest of the Mycotoxins do not appear in milk, since they are not hydroxylated 
in the ruminant’s liver, are considered “secondary” and haven’t received the proper publicity 
until now. Progressively awareness increases and as the saying goes, “the more you look, the 
more you will find”. 
4.4 Technological framework 
As discussed earlier, methods have evolved and compounds such as Mycotoxins can be detected 
and quantified with high precision and accuracy. A network of different institutions using 
different methods, which promise high margins to the manufacturers, create a web of 
overlapping protecting factors which contribute in an overall containment of any Mycotoxin 
crisis. 
Chromatography, ELISA and Lateral-flow methods combined with mathematically oriented 
software have upgraded significantly the process of extrapolating, storing and analyzing data 
related with testing. Information flow has been one of the main impediments in preventing or at 
least containing the past Mycotoxin crisis. Due to this fact tools like Excel have been linked to the 
software of most manufacturers, in order to export data which can be easily read by the people 
in the public institutions. 
Allergens are also another concern in modern food industries but also in wholesale and retail 
stores. The official method for Allergens is ELISA, but the market revolves mainly around the 
Lateral-flow method. Finally, antibiotic residues in milk are possibly the most mature market in 
physico-chemical diagnostics worldwide. Testing in this case also, is based on immunoassay 
principles.  
It is evident, that due to the fact the same methods are used in order to detect and quantify the 
number of parameters, will facilitate the familiarization of the technicians to the processes and 
enable them to include more and more parameters in their routine.  
Moreover, as immunoassay and especially the ones focused on Mycotoxins, witness a reduction 
in costs of materials year-after-year. Combined with the intense competition between biotech 
companies worldwide and the on-going sector consolidation, resources will be re-allocated to 
R&D in an attempt to attain comparative advantages. Although the biotech sector is price 
sensitive too, it is much less than any other commercial sector. 
4.5 Environmental framework 
Mycotoxins are considered to be naturally created toxin residues, excreted by fungi which are 
present everywhere in nature and can grow under the most favorable conditions. In conditions 
of stress they excrete toxins which will reside, regardless whether the fungi will survive. The 
environmental impact on animals, regardless whether they are ruminants, horses or pets, is 
immense and can cause a slow and painful death. 
The methods used to detect and quantify Mycotoxins used to utilize hazardous chemicals such 
as methanol, ethanol and acetonitrile, but due to the environmental print and disposal issues 
that had arisen, distilled water is currently the main solvent.  
As the public becomes environmentally conscious and awareness increases, Mycotoxins will 
receive a different treatment, not only in terms of detection but also containment. Different 
varieties, more fungus-resistant, will be utilized, plowing and sowing techniques will be 
improved, while irrigation and fertilization will take place under specific conditions, scientifically 
identified. 
Fungi are considered, along with insects, the most potent and devastating enemies of all 
cultivations and both are treated by using fungicides and insecticides.  
A shift in traditional, but obsolete views on agricultural techniques, has been observed during 
the past 20 years. An encouraging example is the no-till farming, which does not allow plowing 
(tilling) in order to preserve soil texture and create less favorable conditions for fungi and insects.  
Fertilizers’ content has also developed in a more “green” direction, attempting to minimize 
residues in the ripen product. In the same direction pesticides and herbicides tend to be easier 
to metabolize, in terms of the plant, in order to have less residues. 
Apparently, there is a global shift towards a more passive protection against foes, which has 
proven that cannot be dealt otherwise. Within this framework, it is evident that environmental 
awareness will be a drive to deal with Mycotoxins as problem deriving from fungi, with the 
contribution of the insects as catalysts. 
 
Ch. 5: SWOT Analysis on 3 Major Competitors 
5.1 Strengths 
Neogen, R-Biopharm and Romer Labs are multinational groups consisted of more than 30 
subsidiaries, established all-around the globe. Their most important asset is their brand. 
Reliability and safety in a sector dealing with food safety, are top priorities, and big food 
companies are willing to pay more in order to achieve top quality.  
Due to high specialization of the sector, it is of great importance to have salespeople focused and 
trained. Due to this, throughout the years, all 3 of them established subsidiaries in order to 
achieve better margins, control quality and optimize sales process, by employing and training 
salespeople. In this way, eventually, all smaller players are left with non-specialized trading 
companies, which employ their resources according to their margins. This fundamental 
disadvantage of smaller corporations has stagnated their profits and enabled the Big 3 to proceed 
by further consolidating the market. 
Consistent promotion and relevant actions through regular participation in exhibitions and 
conferences, in the form of sponsorship and presentations, has gradually enhanced brand 
building. Since Food Safety conferences and exhibitions of high esteem mainly take place in 
Europe and the US, promotional costs are minimal in proportion to the sales and gross margins 
of the major players. Easy branding and cost-effective promotion, coupled with prestige deriving 
from “Made in the US/Germany” have created a long-standing, almost traditional, preference in 
these brands. 
“Super-market positioning”: by offering a broad range of products, selective discounts (counter-
balanced by selective overcharges) big companies facilitate end-users in purchasing processes. 
Economies of scale in full effect; leverage is applied on the average customer who cannot easily 
shift for segments of products to other sources easily. 
Continuous improvement and quality augmentation due to the tax-deductible nature of the R&D 
expenses, combined with a relatively high contribution of human capital, result in the constant 
utilization of human resources. 
Extremely low debt is an uncommon characteristic in technology companies, especially in the US, 
but all three of them have minimal debt, mostly short-term. Investments are financed through 
equity, while shareholder’s have a tight grip on their shares; not more than 20% of Neogen’s 
stocks are free-float. R-Biopharm and Romer Labs are not public. 
Leverage on suppliers of raw materials is a common characteristic in any sector when it comes 
to market leaders. In this case, production of raw materials and consequently vertical integration 
is the main objective. Due to the sector’s high specialization, suppliers are limited and production 
also. Shortages, price volatility and dependence have become an incentive for vertical 
integration, which is partially achieved now.  
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Strengths 
1. Annual increase of sales 
over 20% 
2. Broad network of 
subsidiaries 
3. Complete marketing 
plans 
4. High deductibility of 
R&D investments 
5. Low leverage ratios 
6. Vertical integration by 
encompassing antibody 
production 
Weaknesses 
1. Rigidity of big structures 
2. Inhomogeneous structure 
due to acquisition policy 
3. High pricing 
4. Inability to focus on the 
mycotoxins market 
5. Divergence from 
continuous quality 
improvement doctrine 
6. Weak support mechanisms 
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Opportunities 
1. Growth of Mycotoxin 
testing in advance 
countries 
2. Expansion in untapped 
markets in the advancing 
world 
3. Gradual discovery of more 
mycotoxins 
4. Further legislation actions, 
mainly sophistication 
5. Increase of food, feed and 
milk output due to over-
population 
6. New methods of testing 
Mycotoxins 
Threats 
1. Intensification of 
competition between 
major competitors 
2. Decline of profit margins 
due to competition 
3. Main competitors 
4. New entrants 
5. Financial recession which 
forces companies to cut 
costs 
6. Rising Chinese companies 
with better quality 
products 
 
5.2 Weaknesses 
Growth and evolution bear some inherent disadvantages, such as complexity, role overlapping 
and progressive loss of flexibility. As corporate structures grow, relations and priorities are 
perplexed, resulting in slow movements and inability to maneuver and adjust. Saturation, 
disorientation and lack of homogeneity form the mental background of the company’s 
workforce. 
Expansion achieved through acquisitions and absorptions, inhibits assimilation and incommodes 
any attempts of forming solid strategies in the broad spectrum. Different cultures are blended in 
an environment which can prove to be bewildering, while separate locations impede control and 
a constant overview. 
Inability to focus and customize pricing and products are the main characteristics of any super-
market. As such, the major players, do not discount, adopting a “take it-or-leave it” policy which 
can also leave a small window for manufacturers, providing unique and customized solutions 
accompanied by better prices. 
Quality improvements cannot be applied in every single product code, therefore prioritization of 
some means neglection of others. This can create niche windows for smaller, specialized 
competitors focused on a narrow range of products. Mycotoxins and allergens are the absolute 
examples of such kind of process and results. 
Support becomes standardized and personal relations are replaced by professional attitude, 
which create a rather cold environment between the manufacturer and the end-user. It is 
commonly known that it for any kind of client it is easier to stop buying something top tier from 
an indifferent supplier, than to stop buying an indifferent product from an amiable supplier. 
Table 4. SWOT Analysis on Neogen, R-Biopharm and Romer Labs 
5.3 Opportunities  
A rapidly and steadily growing market, which is gradually abolishing the characteristic of 
seasonality as more knowledge is acquired and food safety is advancing. Mycotoxin prevalence 
is related to weather conditions along with human factors, such as storage and transport 
conditions. This creates a seasonal sequence of “ebbs and tides” according to the growing of the 
plant and the weather conditions during the flowering stage, storage conditions after sowing and 
transport conditions around the globe. 
As trade becomes more and more global, and farms are modernized, which means milk 
production throughout the whole year, feed can be always available. This contributes in 
intensifying grain production in order to increase milk output. In turn, grains are imported and 
do not follow the domestic grain cultivation calendar. Therefore, mycotoxin monitoring becomes 
a routine process which will increase significantly in cases of crisis. 
Due to global warming, countries such as the British Isles and Scandinavia, or Australia and New 
Zealand, which were notorious of being “mycotoxin-free”, have seen a small but alarming 
increase in contamination of domestically produced grains. The intensification of the 
phenomenon will literally create a global market and consolidate mycotoxins as a parameter 
which must be tested equivalently to Salmonella and Listeria. 
 “Masked mycotoxins” are a new chapter which is scientifically composed and paves the way for 
a broader, more solid, legislation which will encompass a much greater number of mycotoxins 
(Molecular Nutrition and Food Research, 2013). Metabolites of the “core toxins”, which are 
legislated today in the EU, will be also regulated since primary research has indicated specific 
cases of extreme toxicity. The “masked ones” are more than 200, but their prevalence in nature 
is scarce; only a group of 20 masked toxins seems to have a considerable presence in grains, but 
their discovery and observation is extremely “young” in scientific proportions. Research of less 
than 10 years cannot be considered as proof, but only an indication. 
As science progresses, and humans keep “digging”, more will be discovered, and mycotoxins will 
be eventually become the main physico-chemical parameter. Pesticide residues were at the same 
primal stage 50 years ago, while today a list of more than 50 pesticides is applied to any control 
implanted within a laboratory. 
In relation to the former discussion, legislation has proven to be insufficient in terms of 
sophistication and austerity. India, Serbia and the US, are just some of the countries which are 
slowly following EU’s footsteps in terms of lowering regulated limits and evolving their legislation 
in terms of specificity. E.g. 6 ppb (parts per billion or μg/kg) of Aflatoxin B1 in figs, are different 
than 6 ppb in corn. Therefore, legislation must become more specific and strict. Of course, 
economic impact must be put on the scale and try to balance the impact on public health. This is 
the reason why Mycotoxin binders (neutralizers) are being developed and resistant varieties are 
ploughed. Systems of control through tillage control, reduction of pesticides and insecticides, 
targeted irrigation are the main pre-emptive actions implemented in advanced countries. 
Another strategical action would be the increase of the storage space per cultivated area, as well 
as improving conditions regarding humidity and temperature. 
Global population will increase further, which translates into increased needs for milk, meat and 
food in general. This means increased commodity production, especially in advancing and third-
world countries, which still haven’t introduced any legislation.  
Apparently, the global pie of mycotoxins will grow further, while competition will shrink, and 
their market shares will be eventually absorbed. These combined conditions specify a future of 
great opportunity and growth. 
5.4 Threats 
Although threats are limited, since barriers to entry are numerous, there are some potential 
“enemies” of the current dominators of the market.  
First of all, as consolidation progresses, buffer companies, minor competitors, will be absorbed 
and major market shares will “meet”. This will translate in a future price war, since for the 
moment growth is created by absorbing market shares of smaller companies. But as the pie will 
grow bigger and competition will become more intense, only mergers (since acquisitions 
between 3 top-tier companies are difficult) will bring the necessary economies of scale, in order 
to preserve the double-digit growth rates. 
Price wars could have limited impact on margins, as long as science progresses and more efficient 
ways of production are implanted; unfortunately, the food testing sector has already reduced its 
production costs to very low levels, while end-user prices are sky-high. E.g. production cost per 
ELISA kit is currently below 20 euros, while the end-user price is more than 350 euros. It is evident 
that both, manufacturing and trading margins have already been deployed, and any reduction in 
price will have a significant impact in margins. That is why the 3 major players have avoided any 
price wars, and have expanded vertically and horizontally, instead of further penetrating the 
market. 
Although there is no cartel and competition is intense, it tries to avoid price dropping in its most 
profitable products, such as Mycotoxins and Allergens. Other product ranges, such as the 
microbiological ones are subject to intense pressure, due to the fact that the Chinese companies 
are growing and offer extremely cheap solutions. 
This is the greatest threat. As numerous sectors in the advanced world shrank due to Chinese, 
cheap competition, food diagnostics are also facing intense competition but not yet a truly 
endangering one. Since food safety implies quality, and quality is needed in order to save money 
by not disposing of the commodity, cheap is not attractive for the major food industries; and it 
will never be. Chinese companies, more than 30, have attained small market shares in the rest of 
the globe, while the Chinese market is slowly squeezing them out. The true threat will be 
incarnated when Chinese companies decide to invest in technology and create high-end products 
at lower, but not cheap prices. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ch. 6: Porter’s Five Forces 
6.1 Low Supplier Power 
The chemical reagents needed in order to produce an ELISA kit, whether it is meant to detect 
allergens or mycotoxins, are quite similar. Lateral-flow tests require less chemical substances, 
but still are composed by a broad range of raw materials. 
Immunoassays are based on the antibody-antigen affinity concept: antibodies able to capture 
and affine with specific antigens (in our case Mycotoxins) and produce colored liquids which will 
in turn be read by a photometer. Density of light measurements going through the liquid, will 
provide light absorbance values which will be extrapolated into Mycotoxin values by using proper 
mathematic equations. 
There are numerous suppliers of antibodies worldwide, providing also other chemical reagents, 
but there is no single supplier which can provide top quality reagents for the whole spectrum. 
Therefore, competition is quite intense. Moreover, this is a niche market where almost all 
manufacturers are small and medium-sized companies, working with quite high margins and 
limited production capacity. 
It is apparent that flexibility in pricing and competition in a segmented market, combined with 
the fact that patents are virtually non-existent in the sector, demonstrate a very low supplier 
power on immunoassay manufacturers. 
6.2 Low Buyer Power 
Due to high consolidation of the current market, buyers which mainly constitute laboratories, 
public or private, and industries, have very few options. As long as quality is the question, then 
there only 2-3 alternatives besides the 3 major players, and even those companies cannot offer 
extremely low prices due to the absence of economies of scale in their structures. 
Chinese manufacturers are growing but still capture less than 10% of any market around the 
globe, except China. These products tend to be extremely cheap, relevant to the quality offered, 
which renders these tests useless and re-directs the buyer back to the major manufacturers. 
Moreover, for the time being, no price wars have erupted, and the big companies prefer to 
safeguard their margins instead of increasing sales exponentially. In other food testing sectors, 
such as in microbiology, prices have dropped and due to the massive scale of production, buyers 
tend to have greater power in relation to their suppliers. 
6.3 High Competitive Rivalry 
Although price wars have not yet occurred, competition in terms of quality is high. Envirologix 
and Charm Sciences in the Lateral-flow market constitute formidable opponents for the big ones, 
due to improved technical characteristics and not at all because of pricing. 
The interesting fact is that neither of these 2 companies has attempted to gain market share by 
competitive pricing, instead, focusing on quality and brand marketing has produced considerable 
results. These 5 players, 3 major and the 2 minor ones, constitute more than 99% of the market 
in Mycotoxins and none of them wishes to sacrifice any part of their margin and stay aggressive 
only in the technical aspect. 
6.4 Low Threat of Substitution 
There is no threat of substitution at all. Since industries decide to control internally but at the 
same time legislation requires the dispatch of samples to be tested externally, the pie can grow 
only bigger. This results in cheaper and faster methods needed, which is exactly why ELISA and 
Lateral-flow are growing and used more and more often, in contrast to chromatographic 
methods which are stagnated for years and gradually declining in the recent past.  
High costs of experiment implementation, equally high maintenance costs and huge initial 
investment costs, coupled by a matching-up of quality by immunoassay methods (ELISA and 
Lateral-flow), have rendered chromatography methods useful only as supplementary or 
confirmatory. 
Time-consuming and incapable of testing multiple samples concurrently resulted in confining the 
market to professional laboratories. The industry adopted immunoassays for all the 
aforementioned reasons, but lately even laboratories are strategically deviating from their past 
steps by using ELISA as a screening method for samples, in terms of positive or negative ones, 
and then testing the positive ones with HPLC or LC/MS-MS. 
As gradually laboratories need to reduce costs and become more flexible, it would be prudent to 
say that not only there is no potential substitute for immunoassays, but instead, immunoassays 
will grow further on expense of chromatography. 
6.5 Low Threat of New Entrants 
As in almost all high-tech sectors, new entries are more and more rare, due to a number of factors 
contributing in rapid consolidation. Acquisitions and mergers eventually will absorb any privately 
funded attempts of entering this biotech market of food testing.  
High initial costs, intensive R&D and a labor-intensive sector in general forbid any medium 
enterprises from building from scratch and growing. Even if some enterprise managed to do so, 
it would be acquired or squeezed-out, depending on its qualities and potential. 
Bigger and consolidated companies employ global, all-seeing eyes which will investigate and 
detect any emerging companies. Moreover, the absence of any state enterprises has limited 
competition to these private entities, which has formed a kind of monopoly, or more precisely 
oligopoly. 
Brand loyalty is extremely high in this sector, since credibility in food safety is necessary. This 
inhibits users from converting to competitors’ products. The aforementioned traits virtually bar 
the entrance for any company which wishes to enter and grow in the food testing market. 
  
 
 
 
 
 
 
 
• High segmentation of antibody producers as well as 
producers of chemical liquids used in Immunoassays 
(ELISA, Lateral-flow). Most big companies produce 
their antibodies, limiting the influence of suppliers.
Low Supplier Power
• Besides the Chinese, continuous rounds of 
consolidation have limited the number of 
manufacturers. There are very few alternatives of 
medium and top-quality products. Neogen, R-
Biopharm and Romer Labs have a combined market 
share of 95% in Mycotoxins.
Low Buyer Power
• Although price wars haven’t occurred yet, the 3 
major players are heavily competing with smaller 
ones like Envirologix and Charm in order to squeeze 
them out of the market, or bring them to a “state of 
acquisition”.
High Competitive 
Rivalry
• Lateral-flow is the future, while ELISA is a timeless 
solution, especially in cases of crisis. In reality, it is 
more probable that these methods substitute the 
major competitor, Chromatographic methods, than 
vice versa. 
Low Threat of 
Substitution
• Due to the market consolidation and pressure on 
margins, it is highly improbable that new companies, 
based on competitive grounds, will appear in the 
market. The initial cost of investment is very high, 
only multinational companies active in relevant 
fields could sustain these costs.
Low Threat of New 
Entrants
Ch. 7: Conclusions 
The Mycotoxin market is a rapidly growing one, containing great opportunities for the rising 
Chinese biotechnology sector, but no space for small and medium enterprises. In the ‘90s and 
‘00s, numerous start-ups had been created all-around the globe and contributed in intense 
competition which subsequently drove R&D and quality.  
Gradual consolidation has changed the mentality of the 2 major players, which 15 years ago were 
nothing more than an average medium company. R&D does not absorb more and more funds, 
while consolidation of market shares is based on marketing factors, such as pricing and 
promotion.  
The entrance of Chinese companies during the past 7 years provoked investments in R&D but 
since the gap is unbridgeable, Neogen & R-Biopharm have decided to focus on absorbing smaller 
western companies. What seems to be unbridgeable is, in reality, just distant. The Chinese 
government has been offering incentives to Chinese biotech companies in order to produce 
cheap products, primarily directed to the internal market.  
The current status implies that they have achieved their goal, partially. In the rest of the world, 
Chinese penetration is insignificant, and the correlation of volumes and prices indicates low 
margins and an eventual withdrawal. Since, Food testing is not a regular consumer market, cheap 
low-quality products will not survive. The message coming from the Chinese market is that of 
increasing sophistication in terms of demand from the food industry, and some first indications 
if bigger biotech companies trying to meet this demand. 
Within 2017, the first consolidation round of the Chinese food testing producers started. The 
acquirers are not European companies, but domestic ones which are subsidized by the 
government in order to create “national champions”. There are also indications that quality has 
become a goal worth striving for. Specifically, Evergreen produced the first ELISA kits which can 
compete on better terms the EU and American producers. This happened in late 2017, which 
means that by 2019 a solid impression will be formed, whether this is a temporary phenomenon, 
or a long-term, broader trend. 
If the Chinese manage to close the quality gap, this will force major players to further consolidate 
their position, while investments will sky-rocket, resulting in favor of public health and the food 
industry. Unfortunately, the door for US or EU startups will be closed once and for all, as it 
happened in different sectors regarding technology and consumer goods, such as electronics.  
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